Company profile for Meissa Vaccines

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens. Our passion is child health, but our vaccine programs have the potential to benefit multiple age and population groups. Successful vaccine...
Meissa Vaccines is a pharmaceutical start-up company focused on advancement of unmet vaccines against viruses that cause serious human diseases, such as respiratory syncytial virus (RSV). Our innovative platform technology for viral genetic engineering can be applied to multiple pathogens. Our passion is child health, but our vaccine programs have the potential to benefit multiple age and population groups. Successful vaccines for RSV and related viruses will have widespread benefits for society and families.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
JLABS, 329 Oyster Point Boulevard, 3rd Floor South San Francisco, CA 94080
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/meissa-vaccines-future-limbo-due-current-fundraising-climate-ceo

FIERCE BIOTECH
05 Mar 2024

https://www.businesswire.com/news/home/20230808124808/en

BUSINESSWIRE
08 Aug 2023

https://exothera.world/meissa-vaccines-enters-into-cgmp-manufacturing-agreement-for-pediatric-rsv-vaccine-candidate-for-phase-2-clinical-trials/

PRESS RELEASE
28 Jun 2023

https://www.businesswire.com/news/home/20221107005432/en

BUSINESSWIRE
07 Nov 2022

https://www.businesswire.com/news/home/20220726006074/en

BUSINESSWIRE
27 Jul 2022

https://www.businesswire.com/news/home/20220711005060/en

BUSINESSWIRE
11 Jul 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty